Registration number: SC694948

K4 Genomics Limited

Contents

Company Information	1
Balance Sheet	2
Notes to the Unaudited Financial Statements	3 to 5

K4 Genomics Limited

Company Information

Directors

D Kinane J Kinane L Kinane R Kinane

Registered office

Unit 26, Dunfermline Business Centre Izatt Avenue Dunfermline Fife KY11 3BZ

Accountants

M&S Accountancy and Taxation Unit 26, Dunfermline Business Centre Izatt Avenue Dunfermline Fife KY11 3BZ

K4 Genomics Limited

(Registration number: SC694948)
Balance Sheet as at 30 April 2025

	Note	2025 £	2024 £
Fixed assets
Tangible assets	4	125	186
Current assets
Debtors	5	7,640	22,503
Cash at bank and in hand		135,022	152,560
		142,662	175,063
Creditors: Amounts falling due within one year	6	(2,625)	(17,593)
Net current assets		140,037	157,470
Total assets less current liabilities		140,162	157,656
Provisions for liabilities		(24)	(35)
Net assets		140,138	157,621
Capital and reserves
Called up share capital	7	100	100
Retained earnings		140,038	157,521
Shareholders' funds		140,138	157,621

For the financial year ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

•	The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
•	The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 3 September 2025 and signed on its behalf by:
 

......................................... D Kinane Director

K4 Genomics Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

1	General information

The company is a private company limited by share capital, incorporated in Scotland.

The address of its registered office is:
Unit 26, Dunfermline Business Centre
Izatt Avenue
Dunfermline
Fife
KY11 3BZ

These financial statements were authorised for issue by the Board on 3 September 2025.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Going concern

The directors believe that the company is experiencing good levels of sales growth and profitability, and that it is well placed to manage its business risks successfully. Accordingly, they have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the financial statements.

Tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The companys liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

Tangible assets

Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:

Computer Equipment 33% Reducing Balance

K4 Genomics Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

Provisions

Provisions are recognised when the company has a present obligation as a result of a past event which it is more probable than not will result in an outflow of economic benefits that can be reasonably estimated.

Dividends

Proposed dividends are only included as liabilities in the balance sheet when their payment has been approved by the shareholders prior to the balance sheet date.

Financial instruments

The company has elected to apply the provisions of Section 11 Basic Financial Instruments and Section 12 Other Financial Instruments Issues of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
 

3	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 4 (2024 - 4).

4	Tangible assets

	Office equipment £	Total £
Cost or valuation
At 1 May 2024	617	617
At 30 April 2025	617	617
Depreciation
At 1 May 2024	431	431
Charge for the year	61	61
At 30 April 2025	492	492
Carrying amount
At 30 April 2025	125	125
At 30 April 2024	186	186

5

Debtors

K4 Genomics Limited

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2025

Current	2025 £	2024 £
Trade debtors	-	15,000
Other debtors	7,640	7,503
	7,640	22,503

6

Creditors

Creditors: amounts falling due within one year

	2025 £	2024 £
Trade creditors	480	-
Taxation and social security	-	15,353
Accruals and deferred income	1,645	2,240
Other creditors	500	-
	2,625	17,593

7	Share capital

Allotted, called up and fully paid shares

	2025		2024
	No.	£	No.	£
A Ordinary of £1 each	10	10	10	10
B Ordinary of £1 each	40	40	40	40
C Ordinary of £1 each	10	10	10	10
D Ordinary of £1 each	40	40	40	40
	100	100	100	100

8	Related party transactions

Transactions with directors

2025	At 1 May 2024 £	Advances to director £	Repayments by director £	At 30 April 2025 £
D Kinane
	7,085	105	(105)	7,085